- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01076530
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors
Study Overview
Status
Conditions
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Ependymoma
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Extra-adrenal Paraganglioma
- Childhood Choroid Plexus Tumor
- Childhood Craniopharyngioma
- Childhood Ependymoblastoma
- Childhood Grade I Meningioma
- Childhood Grade II Meningioma
- Childhood Grade III Meningioma
- Childhood High-grade Cerebellar Astrocytoma
- Childhood High-grade Cerebral Astrocytoma
- Childhood Infratentorial Ependymoma
- Childhood Low-grade Cerebellar Astrocytoma
- Childhood Low-grade Cerebral Astrocytoma
- Childhood Medulloepithelioma
- Childhood Supratentorial Ependymoma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germinoma
- Childhood Central Nervous System Mixed Germ Cell Tumor
- Childhood Central Nervous System Teratoma
- Childhood Central Nervous System Yolk Sac Tumor
- Childhood Mixed Glioma
- Childhood Oligodendroglioma
- Recurrent Childhood Central Nervous System Embryonal Tumor
- Recurrent Childhood Spinal Cord Neoplasm
- Childhood Central Nervous System Embryonal Tumor
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the maximum tolerated dose and/or recommended phase II dose of vorinostat in combination with temozolomide in pediatric patients with relapsed or refractory primary CNS tumors.
II. To define and describe the toxicities of this regimen in these patients.
SECONDARY OBJECTIVES:
I. To preliminarily define the antitumor activity of this regimen within the confines of a phase I study.
II. To characterize the pharmacokinetic parameters of vorinostat in these patients.
III. To determine whether acetylated histones in peripheral blood mononuclear cells can be identified as a surrogate marker of the biologic effect of vorinostat at various treatment doses.
IV. To assess the feasibility of collecting and analyzing serum DNA for methylation of the MGMT promoter and describe the relationship between promoter methylation and clinical responses within the confines of this phase I study.
OUTLINE: This is a multicenter, dose-escalation study of vorinostat.
Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
Patients may undergo blood sample collection periodically for pharmacokinetic and correlative laboratory studies by western blotting and MGMT promoter methylation assays.
After completion of study therapy, patients are followed up for 30 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital For Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- Hospital Sainte-Justine
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Childrens Memorial Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- C S Mott Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Medical Center-Fairview
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed CNS malignancy at original diagnosis or relapse
- Histologic confirmation not required for patients with intrinsic brain stem tumors, optic pathway gliomas, or pineal tumors provided CSF or serum tumor markers, including alpha-fetoprotein orbeta-HCG, are elevated
- Recurrent or refractory spinal cord tumors allowed
- Measurable or evaluable disease
- No known curative therapy or therapy proven to prolong survival with an acceptable quality of life
Karnofsky performance status (PS) 50-100% (for patients > 16 years of age) OR Lansky PS 50-100% (for patients ≤ 16 years of age)
- Neurological deficits must have been relatively stable for ≥ 1 week before study entry
- Patients unable to walk due to paralysis, but who are up in a wheelchair, are considered ambulatory for the purpose of assessing performance status
- ANC ≥ 1,000/μL
- Platelet count ≥ 100,000/μL (transfusion independent, defined as no platelet transfusion within the past 7 days)
- Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)
Creatinine clearance or radioisotope GFR ≥ 70mL/min OR maximum serum creatinine based on age and/or gender as follows:
- 0.6 mg/dL (1 year of age)
- 0.8 mg/dL (2 to 5 years of age)
- 1.0 mg/dL (6 to 9 years of age)
- 1.2 mg/dL (10 to 12 years of age)
- 1.5 mg/dL (males) or 1.4 mg/dL (females) (13 to 15 years of age)
- 1.7 mg/dL (males) or 1.4 mg/dL (females) (≥ 16 years of age)
- Bilirubin ≤ 1.5 times upper limit of normal
- ALT ≤ 110 U/L
- Serum albumin ≥ 2 g/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to swallow capsules or liquid
- Seizure disorder allowed provided it is well controlled with nonenzyme-inducing anticonvulsants
- No pre-existing QTc ≥ 450 msec
- No uncontrolled infection
- No patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of study
- Fully recovered from prior chemotherapy, immunotherapy, or radiotherapy
- More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)
- At least 7 days since prior hematopoietic growth factors
- At least 7 days since prior biologic agent (antineoplastic agent)
- At least 7 days or 3 half-lives, whichever is longer, since prior monoclonal antibodies
- More than 2 weeks since prior local palliative radiotherapy (small port)
- At least 6 months since prior total-body radiotherapy (TBI), craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis
- At least 6 weeks since other prior substantial bone marrow radiotherapy
At least 3 months since prior stem cell transplantation or rescue (without TBI)
- No evidence of active graft-vs-host disease
- At least 2 weeks since prior valproic acid
- No prior vorinostat
- Prior temozolomide allowed provided there was no progressive disease during or within 1 month after completion of treatment
- Concurrent corticosteroids allowed provided patient has been on a stable or decreasing dose for ≥ 7 days before study entry
- No other concurrent investigational drugs
- No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy
- No concurrent enzyme-inducing anticonvulsants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients receive oral vorinostat and oral temozolomide once daily on days 1-5.
Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
|
Other Names:
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT using NCI CTCAE version 4.0
Time Frame: 28 days
|
In addition to determination of the MTD, a descriptive summary of all toxicities will be reported.
|
28 days
|
Pharmacokinetic parameters of vorinostat in combination with temozolomide
Time Frame: Pre-dose, 15 and 30 minutes, 1, 2, 4, 6, 8, and 24 hours
|
The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).
|
Pre-dose, 15 and 30 minutes, 1, 2, 4, 6, 8, and 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response assessed according to RECIST criteria
Time Frame: Up to 30 days
|
Will be reported descriptively.
|
Up to 30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Trent Hummel, COG Phase I Consortium
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Musculoskeletal Diseases
- Neoplasms, Neuroepithelial
- Neoplasms, Nerve Tissue
- Spinal Cord Diseases
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Bone Diseases
- Pregnancy Complications
- Neoplasms, Complex and Mixed
- Neuroendocrine Tumors
- Neoplasms, Vascular Tissue
- Pregnancy Complications, Neoplastic
- Meningeal Neoplasms
- Trophoblastic Neoplasms
- Bone Neoplasms
- Mesonephroma
- Cerebral Ventricle Neoplasms
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Glioblastoma
- Recurrence
- Glioma
- Ependymoma
- Medulloblastoma
- Rhabdoid Tumor
- Astrocytoma
- Oligodendroglioma
- Meningioma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Teratoma
- Choriocarcinoma
- Paraganglioma
- Spinal Cord Neoplasms
- Pinealoma
- Endodermal Sinus Tumor
- Germinoma
- Craniopharyngioma
- Adamantinoma
- Paraganglioma, Extra-Adrenal
- Choroid Plexus Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Histone Deacetylase Inhibitors
- Temozolomide
- Vorinostat
Other Study ID Numbers
- NCI-2011-02011
- U01CA097452 (U.S. NIH Grant/Contract)
- ADVL0819
- CDR0000664388
- COG-ADVL0819
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Childhood Medulloblastoma
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Ependymoma | Recurrent MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Oligodendroglioma | Childhood Cerebral Anaplastic AstrocytomaUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)TerminatedRecurrent Childhood Medulloblastoma | Childhood Choroid Plexus Tumor | Childhood Ependymoblastoma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Childhood Medulloepithelioma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGlioma | Recurrent Childhood Medulloblastoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Diffuse Intrinsic Pontine Glioma | Refractory Brain Neoplasm | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Glioblastoma | Recurrent Primitive Neuroectodermal Tumor | Childhood Astrocytoma and other conditionsUnited States
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...CompletedMedulloblastoma Recurrent | Atypical Teratoid/Rhabdoid Tumor | Medulloblastoma, Childhood, RecurrentUnited States
Clinical Trials on pharmacological study
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Universitätsmedizin MannheimHeidelberg UniversityUnknownLung Cancer | Brain and Central Nervous System TumorsGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Peloton Therapeutics, Inc.CompletedRecurrent GlioblastomaUnited States
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Visual Pathway Glioma | Childhood Central Nervous System Germ Cell Tumor | Childhood Central Nervous System Choriocarcinoma | Childhood Central... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary SyndromeUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage...United States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Proliferations Associated With Down SyndromeUnited States, Canada, Australia, Puerto Rico